On February 23, the reporter of Securities Daily learned from Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) that in order to implement the decisions and arrangements of the CPC Central Committee and the State Council and effectively support the prevention and control of covid-19 epidemic in the HKSAR, the Ministry of industry and information technology took the lead in Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) emergency production deployment through Guangdong Zhongnanshan medical foundation China Population Welfare Foundation and other institutions donated 13.65 million yuan (about HK $16.8 million) of epidemic prevention materials to support the epidemic prevention and control work in Hong Kong, China, including 200000 boxes of Lianhua Qingwen capsules and Lianhua Qingke tablets, Lianhua respiratory health bag, Lianhua Qingwen antibacterial and antiviral mask, etc.
As the general manager of Hong Kong Yuquan Co., Ltd., we hope to join hands with Yuquan in Hong Kong. "I believe that with the support of the central government, we will unite as one, and Hong Kong will quickly win the victory in the fight against the epidemic and restore normal living order as soon as possible."
Lianhua Qingwen capsule, as a representative product of the "three drugs and three parties" of Chinese traditional medicine, was approved for listing in Hong Kong as a "Chinese patent medicine" in June 2018. "Lianhua Qingwen has antiviral and anti-inflammatory effects on covid-19 virus" published by the State Key Laboratory of respiratory diseases in the mainstream journal pharmacological research in the international pharmacology community confirmed that Lianhua Qingwen exerts its anti-covid-19 activity by inhibiting virus replication and inhibiting the expression of inflammatory factors in host cells. The latest research also found that even huaqingwen showed a stable antiviral effect in vitro on variant strains such as alpha, beta and delta.
Since the advent of SARS in 2003, Lianhua Qingwen has been recommended for more than 20 times at the national level in public health events such as influenza A (H1N1), influenza B, avian influenza and COVID-19 pneumonia. It has become a representative drug for public health emergencies.
At present, Lianhua Qingwen has been approved for listing in nearly 30 countries and regions such as Russia, Canada, Brazil, Indonesia, Kuwait and Cambodia, and has entered the white list of anti epidemic drugs and home treatment programs for patients with mild diseases in many countries.
According to Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) , Lianhua respiratory health products draw the essence of the main drugs of Lianhua Qingwen, and have the same anti-inflammatory and anti viral genes. Lianhua Qingke tablet, as a patented traditional Chinese medicine approved during covid-19 pneumonia in May 2020, has the effects of dispersing lung and relieving heat, resolving phlegm and relieving cough, and has multiple advantages for cold, influenza and cough caused by covid-19; Lianhua respiratory health protection products are developed with the concept of "prevention before disease", which can effectively block the three transmission paths of bacteria "human to human", "material to human" and "environment to human", and provide people with all-round health protection.
